Phlebotomy Study of Testosterone Undecanoate

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions
Hypogonadism
Interventions
DRUG

Oral Testosterone Undecanoate

Subjects will receive a single dose containing 158 mg of testosterone undecanoate, equivalent to 200 mg testosterone.

Trial Locations (1)

90502

Los Angeles Biomedical Research Institute, Torrance

Sponsors
All Listed Sponsors
lead

Clarus Therapeutics, Inc.

INDUSTRY

NCT02670343 - Phlebotomy Study of Testosterone Undecanoate | Biotech Hunter | Biotech Hunter